Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations.

Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations.

To induce a deployable level of efficacy, a successful malaria vaccine would likely benefit from both potent cellular and humoral immunity. These requirements are met by a heterologous prime-boost immunization strategy employing a chimpanzee adenovirus vector followed by modified vaccinia Ankara (MV...

Bibliografski detalji
Glavni autori:	Kimani, D, Jagne, Y, Cox, M, Kimani, E, Bliss, C, Gitau, E, Ogwang, C, Afolabi, M, Bowyer, G, Collins, K, Edwards, N, Hodgson, S, Duncan, C, Spencer, A, Knight, MG, Drammeh, A, Anagnostou, N, Berrie, E, Moyle, S, Gilbert, S, Soipei, P, Okebe, J, Colloca, S, Cortese, R, Viebig, N
Format:	Journal article
Jezik:	English
Izdano:	2014

Slični predmeti

Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.
od: Ogwang, C, i dr.
Izdano: (2013)

Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.
od: Caroline Ogwang, i dr.
Izdano: (2013-01-01)

Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals.
od: Hodgson, S, i dr.
Izdano: (2014)

ChAd63-MVA-vectored blood-stage Malaria vaccines targeting MSP1 and AMA1: Assessment of efficacy against mosquito bite challenge in humans
od: Sheehy, S, i dr.
Izdano: (2012)

Evaluation of the efficacy of chad63-mva vectored vaccines expressing circumsporozoite protein and me-trap against controlled human malaria infection in malaria-naive individuals
od: Hodgson, SH, i dr.
Izdano: (2014)

ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans.
od: Sheehy, S, i dr.
Izdano: (2012)

First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children
od: Tiono, AB, i dr.
Izdano: (2018)

A Phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS
od: De Barra, E, i dr.
Izdano: (2014)

Safety and high level efficacy of the combination malaria vaccine regimen of RTS,S/AS01B with ChAd-MVA vectored vaccines expressing ME-TRAP
od: Rampling, T, i dr.
Izdano: (2016)

Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African children and infants
od: Bliss, C, i dr.
Izdano: (2016)

First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children.
od: Alfred B Tiono, i dr.
Izdano: (2018-01-01)

Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure
od: Biswas, S, i dr.
Izdano: (2014)

A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS.
od: Eoghan de Barra, i dr.
Izdano: (2014-01-01)

Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation
od: Ewer, K, i dr.
Izdano: (2013)

Phase Ia clinical evaluation of the plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors
od: Sheehy, S, i dr.
Izdano: (2011)

Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors.
od: Sheehy, S, i dr.
Izdano: (2011)

Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection.
od: Elias, S, i dr.
Izdano: (2014)

Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure.
od: Sumi Biswas, i dr.
Izdano: (2014-01-01)

Impact of exposure to malaria and nutritional status on responses to the experimental malaria vaccine ChAd63 MVA ME-TRAP in 5-17 month-old children in Burkina Faso
od: Richard Morter, i dr.
Izdano: (2022-12-01)

Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors.
od: Sheehy, S, i dr.
Izdano: (2012)

Safety and Efficacy of Novel Malaria Vaccine Regimens of RTS,S/AS01B alone, or with Concomitant ChAd63-MVA Vectored Vaccines Expressing ME-TRAP
od: Rampling, T, i dr.
Izdano: (2018)

Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal.
od: Mensah, V, i dr.
Izdano: (2016)

Impact of exposure to malaria and nutritional status on responses to the experimental malaria vaccine ChAd63 MVA ME-TRAP in 5-17 month-old children in Burkina Faso
od: Morter, R, i dr.
Izdano: (2022)

Viral vector malaria vaccines induce high-level T cell and antibody responses in West African children and infants
od: Bliss, C, i dr.
Izdano: (2016)

Stratification and Adaptation of Malaria Control Interventions in Chad
od: Mahamat Idriss Djaskano, i dr.
Izdano: (2023-09-01)

Durability of immune responses induced by three leading candidate ebola vaccine regimes; rVSV ZEBOV, ChAd3 EBO Z-MVA BN-Filo and AdHu26.ZEBOV-MVA BN Filo
od: Ewer, K, i dr.
Izdano: (2018)

Generation of multivalent recombinant MVA vaccines for malaria
od: Orubu, T
Izdano: (2012)

Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal.
od: Victorine A Mensah, i dr.
Izdano: (2016-01-01)

CD4+ T cell responses to the Plasmodium falciparum erythrocyte membrane protein 1 in children with mild malaria.
od: Gitau, E, i dr.
Izdano: (2014)

Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial
od: Hans de Graaf, i dr.
Izdano: (2021-07-01)

Safety and immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I first-in-human trial
od: de Graaf, H, i dr.
Izdano: (2021)

Safety and immunogenicity of the novel plasmodium falciparum blood-stage vaccine chad63-mva rh5 in a phase ia clinical trial
od: Payne, R, i dr.
Izdano: (2017)

Review Article: blood-brain barrier in falciparum malaria.
od: Gitau, E, i dr.
Izdano: (2005)

High insecticide resistance in the major malaria vector Anopheles coluzzii in Chad Republic
od: Sulaiman S. Ibrahim, i dr.
Izdano: (2019-12-01)

Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates
od: Capone, S, i dr.
Izdano: (2010)

Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates.
od: Capone, S, i dr.
Izdano: (2010)

The Effect of Previous Exposure to Malaria Infection and Clinical Malaria Episodes on the Immune Response to the Two-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen
od: Daniela Manno, i dr.
Izdano: (2023-08-01)

Safety and immunogenicity of the heterologous prime-boost ebolavirus vaccine regimen CHAD3-EBO Z and MVA-BN (R) FILO in healthy UK adults
od: Rampling, T, i dr.
Izdano: (2015)

Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector.
od: O'Hara, G, i dr.
Izdano: (2012)

Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis.
od: Gilbert, S, i dr.
Izdano: (2006)